195 related articles for article (PubMed ID: 31127397)
1. Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate?
Bowes CD; Lien LF; Butler J
Curr Diab Rep; 2019 May; 19(7):39. PubMed ID: 31127397
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Diabetes in Patients with Heart Failure.
Bowes CD; Lien LF; Butler J
Curr Cardiol Rep; 2018 Aug; 20(10):97. PubMed ID: 30151728
[TBL] [Abstract][Full Text] [Related]
3. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
Nassif ME; Kosiborod M
Am J Cardiol; 2019 Dec; 124 Suppl 1():S12-S19. PubMed ID: 31741435
[TBL] [Abstract][Full Text] [Related]
4. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
[TBL] [Abstract][Full Text] [Related]
5. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
6. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
Secrest MH; Udell JA; Filion KB
Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
[TBL] [Abstract][Full Text] [Related]
7. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
Kramer CK; Ye C; Campbell S; Retnakaran R
JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety outcomes of new antidiabetic therapies.
LeBras MH; Barry AR; Koshman SL
Am J Health Syst Pharm; 2017 Jul; 74(13):970-976. PubMed ID: 28483748
[TBL] [Abstract][Full Text] [Related]
9. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
10. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
Libianto R; Davis TM; Ekinci EI
Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
12. Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.
Sharma A; Butler J; Zieroth S; Giannetti N; Verma S
Diabet Med; 2019 Dec; 36(12):1550-1561. PubMed ID: 31536660
[TBL] [Abstract][Full Text] [Related]
13. Treatment of diabetes and heart failure: a paradigm shift for cardiologists?
Brochu B; Chan M
Curr Opin Cardiol; 2019 Mar; 34(2):207-212. PubMed ID: 30608252
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of cardiovascular outcome trials in type 2 diabetes.
Mellbin LG; Wang A; Rydén L
Herz; 2019 May; 44(3):192-202. PubMed ID: 30805659
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of cardiovascular safety of novel glucose-lowering medications].
Mkrtumyan AM; Markova TN; Mishchenko NK
Kardiologiia; 2019 Jul; 59(7):76-83. PubMed ID: 31322093
[TBL] [Abstract][Full Text] [Related]
16. [Evidence-based reduction of cardiovascular risk in patients with diabetes].
Schütt KA
Herz; 2020 Apr; 45(2):118-121. PubMed ID: 31820029
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular outcome trials of glucose-lowering medications: an update.
Home P
Diabetologia; 2019 Mar; 62(3):357-369. PubMed ID: 30607467
[TBL] [Abstract][Full Text] [Related]
18. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Bonora E; Cigolini M
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
[TBL] [Abstract][Full Text] [Related]
19. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
Bonadonna RC; Borghi C; Consoli A; Volpe M
Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
[TBL] [Abstract][Full Text] [Related]
20. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
